News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would like the thank the sellers of the cheap shares.
That is the best presentation Mike has ever done that I have seen.
Thanks for the link. Second Interview is near the close today on Emerging Markets. Access is free
Seriously, do you not know how to think outside of the box?
Public companies do not make those kinds of comments to the Public, until the deal is done, and then it is too late to accumulate cheap shares.
BIXT gang buster live presentation on You Tube just ended. I will share to link to reruns when it is out.
Another interview is on Emerging Markets late tomorrow.
They stock is crazy undervalued
What you believe or do not believe is your problem. Not mine.
The biotech world is a small world. All BIXT needs to do is find one ethical Cancer MD and Cancer center to run a Prolectin-M test for 7 days on a Cancer patient whose Galectin-3 levels are too high for the Merck Keytruda cancer drug to work.
Once the Galecti-3 level is super low, then let the patient get the Merck Keytruda cancer drug. The patient gets cured, and everybody wins.
Option 2 is for the cancer patient to die, with no treatment.
Merck Looses, the Patient looses...
If you were the management team at $MRK #Merck, and BIXT popped up on your radar with a non toxic oral pill that can 3X increase the Cure rate of your #Keytruday #Cancer drug, that already has a Billion dollar a year revenue, what would you do?
1) Ignore it? LO
2) Make a JV deal with $BIXT?
3) Sit on your ass and let another drug firm beat you to a deal?
Any day, means any day, because there will be zero warning in advance for that kind of deal.
Go read and watch all the historical updates and official what if's from BIXT, CCO updates and explanations on the various ways they are working on getting funding on many fronts. It does not take a genius to figure out what all BIXT is in working on, and how they might fund each step. No one else has the AI perfected Galetin-3 inhibitor BIXT has patented for 60+ viruses, that can also 1-3X increase the cure rate of existing cancer drugs / Chemo, and that already passed the recent Phase II dosing trial for Covid19 (all strains) that is now known to block H5N1 Bird flu. USDA field Trial funding to the University that BIXT is teamed up with now, Univ of Georgia, could be released any week now.
No one should be selling dips, they should be buying dips like me, if they can
The News fuses are not 10 years on BIXT like most similar small Biotechs. The BIXT Fuses all super short as the recent 300% rally demonstrated.
You are know to biased, so fell free to miss the bargains. Some one has chase and buy in $$$ Land. Might as well be you?
They have a 10 Million dollar grant to fund the Synthetic oxygen carrier molecule research to completion.
They completed the Phase II Covid19 dosing trial they needed money for last year. That makes them ready for a funding deal / JV for the Long Haul Covid19 US FDA trial to start.
The USDA is about to issue a 2 Million dollar grant to the University Of Georgia to do the field trials for the BIXT Prolectin-M Galectin-3, AI perfected and patent protected 60+ Virus antiviral that also stops H5N1 Bird flu from accessing and infecting Bird and mammal cells.
And now they have the prefect solution for $MRK, Merck's #Keytruda cancer drug that does not work on 75% of the cancer patients because of their High Galectin-3 blood levels, that BIXT Prolectim-M and I can eliminate.
JV with Merck that would increase the $MRK Merck Revenue from 1 to 4 Billion dollars/year, could drop as a PR any day.
Chasers will chase, I am and have been accumulating, and will keep on accumulating.
Only a fool does not buy the 50-95% off discount on this $BIXT stock right now.
I am buying the $BIXT dips because I know how huge what they have is.
Broad spectrum antiviral and Cancer...
They are the leader in the Galectin-3 field,, and the competition lost 700 million of funding to study mRNA vaccines for decade for Birdflu, while we all die.
Best news for $BIXT since the Univ of Georgia - BIXT team filed for the Bird flu trial study funding, for the Prolectin-M we know will work
https://www.thegatewaypundit.com/2025/06/rfk-jr-appoints-several-prominent-critics-covid-19/
The $BIXT stars are lining up. I saw this a day ago posted by an MD, saying there was concern in China as MDs were dropping dead on the job in China, from the new Covid strain. While RFK killed the 700 Million in funding for Moderna Birdflu (That is good news for all), they killed the next Flu shot vaccine funding, and as your news shows, they fired the Vaccine advisory committee (most of them).
Now this, confirms the China News, confirmed by Hong Kong
https://www.cbsnews.com/news/us-reports-cases-new-covid-variant-nb-1-8-1-behind-surge-china/
There's Vaccines and then there is BIXT. Best be loading!!!
2 Milllion in debt?!! This is the OTC my good man. If they were 20 million or 200 million in debt I would fret but not for peanuts in debt.
Sorry but I have not read "but we have no money". Now should they be smart which I get the feeling they are, then I would be in talks
with collaborators to partner in trials and studies. Watch.
We all missed another Video interview update folks
Really, this is quite an Impressive presentation. 100% professional.
Burn baby burn. Would love to see Fuzzy Fixer Fizer have that problem too.
Today's $BIXT share price makes zero sense. People should be swarming the ask slapping it silly today. I Guess everyone including Lame Street and Goldman Sucks missed the news. So much for AI the BS about efficient markets.
Thanks for the cheapies fools. Got anymore?
Holy Cow bat man, look at this, all 42 pages, I missed earlier:
https://cdn.prod.website-files.com/5cd9cf5f4183373f6b248799/64f77bdeed36fb8767af6f94_Bioxytran%20Long-COVID%20Presentation%20UPDATED.pdf
Nothing more powerful and beautiful as people expressing the truth in force.
That is huge news and great news for BIXT and their 60+ Virus antiviral
[/img]
Whale ask just got ate, whole, 100K share bought like it was nothing. BIXT is waking up folks. Lots of news eye on this.
This is one of the best ethical investments on the market right now.
[/img]https://cdn.discordapp.com/attachments/1071577038294614066/1376952958129799300/image.png?ex=683732df&is=6835e15f&hm=4e60f78bc0074164a2fb5384c66b62e3ca3b318b545d9dacc53c955e2b843b38&[/img]
You know that University of Georgia already applied for the USDA grant last week using the BIXT water soluble antiviral #Prolectin-M as it's top choice for the trials/studies right?
I hear there are only 6-8 labs in the US that can even run the trials, that have the permits to handle H5N1 virus. University of Georgia is one, and they are experts on Chickens in their Ag department.
The grants are limited to 2 Million dollars and with only 6-8 possible applicants, and a 2 Million dollar limit, the USDA is over funded by at least 88 Million dollars.
$BIXT
The instant reply of the interview this week is here
Science behind the product:
Bioxytran has a significant subject matter expertise in the formulation of an oral form of a Galectin inhibitor. The company was able to capitalize on Dr Platt’s many years of research and recent peer reviewed articles on Galectins and COVID-19 to quickly complete the proof of concept phase. Dr Platt, who has a PhD in carbohydrate chemistry, was the first scientist to express the gene, which he named Galectin, 28 years ago.
We know that the N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein scientists have elucidated a galectin fold on the side of the spike that should have a binding affinity to sugar carbohydrates like ProLectin. Animal studies on influenza (needs reference) have demonstrated that inhibiting galectin-1 improves outcomes in lethal influenza models. Other animal’s models show that galectin inhibitors act as immune modulators in cancer and other diseases.
Our molecule is designed to stay in the blood and attach to the COVID-19 protein spikes. When the inhibitor binds to the spike it effectively tags the virus for elimination through the liver. Galectins are theorized to participate in the antiviral defense which starts at the initial recognition of the virus before it binds to the entry receptor all the way through the activation and amplification of the innate and adaptive responses of the immune system.
Galectins are adhesion molecules and allow neutrophils to stay prepositioned in the pulmonary capillaries for a quicker reaction in case of infection. They are also involved in the trafficking of macrophages responsible for the inflammatory cycle of the cytokine storm. Additionally, research in cancer and viruses has demonstrated that galectins form a plaque on CD-8 T-cells which inhibit the adaptive immune response. Therefore, our galectin antagonist should not only reduce the viral load of COVID-19, but also modulate the immune response by reducing the trafficking of macrophages thereby reducing the cytokine storm and returning the immune system to homeostasis. We also expect it to restore functionality to the adaptive immune system by reactivating anergic T-cells that were covered in galectin plaque.
If given early in the disease, we believe that our first drug candidate, galectin antagonist, will block viral entry and tag the virus for elimination through the liver. In theory the virus will be eliminated from the blood stream after a couple of treatments. At a later stage in the disease pathology, a more potent IV solution, ProLectin- I could restore adaptive immune function to help eradicate the virus from the body. In severe COVID-19 patients the drug, ProLectin-A, could reduce the trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis. ProLectin-F is designed to treat organ damage after virus is eliminated from the system.
Galectin Antagonist is the first-in-class of inhibitors to cover a range of Galectins associated with viral replication adhesion and immune system blockage (not modulation). The N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein the Galectin fold on the side of the spike has a binding affinity to sugar carbohydrates like Galectin Antagonist.
Galectins are members of a family of proteins called lectins. These proteins interact with carbohydrate sugars located on the surface, in between cells, and on the Galectin fold of the spike protein. These interactions cause the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain (CRD), within the lectins. Galectins have a CRD that binds specifically to sugar molecules. They have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections Galectins are upregulated and downregulated based on the type of virus.
Bioxytran intends to develop and, through third party contracts, manufacture oxygen therapeutics. Our oxygen therapeutics are a new class of pharmaceuticals that are administered intravenously to transport oxygen to the body’s tissues. Currently there are four drug candidates to treat a stroke. Abciximab from Eli Lilly is a platelet aggregation inhibitor. Clinical trials show little advantage over placebos and could lead to dangerous side effects, including more bleeding in patients. Cerovive from AstraZeneca is a Nitrone-based neuro protectant currently in phase III clinical trials which shows no significant benefit over placebos with respect to changes in neurological impairment as measured by the national institute of health stroke scale. Candesartan, from AstraZeneca, is an angiotensin receptor blocker which was used to control blood pressure. Its efficacy in stroke patients still must be proven. Ancod from Knoll Pharmaceuticals is an anti-coagulant that acts by breaking down the fibrinogen. It increases the risk of hemorrhage similar to those associated with tPA. Using our issued patents and proprietary technology, we intend to develop and manufacture BXT-25 and similar drugs for applications including treatment of stroke conditions. Our patent position consists of 2 parts: a patent related to our co-polymer technology issued in 2009 by the United States Patent and Trademark Office expiring in February 2029 (method patent for producing modified pectins consisting of neutral sugar sequences ) and assigned to us outright by David Platt; various methods to stabilize a single hemoglobin molecule that are in the public domain; Dr. Platt did not receive any compensation from the Company in consideration of his assignment of the patent. Additionally, Bioxytran, Inc. has an exclusive license for an FDA approved technology monitoring NADH (OxySense), the control marker in the body’s conversion of Oxygen to Energy, or the energy generating chain. The technology provides a clinical end-point for measuring oxygen supply to the brain in real-time. OxySense, developed by MDX LifeSciences, Inc., provide us with a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disease indications resulting from hypoxia. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring) to Bioxytran for clinical monitoring of oxygen delivery through oxygen carriers.
AI
